If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of ...

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

Big shifts GLP-1 market include FDA approval of oral weight loss drugs and expanded Medicare coverage starting July 2024 for key GLP-1 therapies.

A Cleveland Clinic study suggests GLP-1 weight loss drugs may help slow the spread of some obesity-related cancers.

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

The outgoing Biden administration in its waning days sought to extend Medicare and Medicaid coverage to Wegovy and Zepbound, but the Trump administration shelved that effort. The deal announced ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide ...

Retatrutide, Eli Lilly’s next obesity shot, showed far more weight loss in clinical trial patients than other blockbuster ...

Wegovy and Zepbound, two popular weight loss GLP-1 medications, would remain cost-effective at a higher price, according to an Oct. 29 revised report from the Institute for Clinical and Economic ...

A GLP-1 Bridge pilot program launching in July can significantly reduce the price you pay for weight loss meds. Here’s how to ...

Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy ...